Gene expression profiling in primary AML cells treated with decitabine and cytarabine

GSE40442

Homo sapiens

66 Downloadable Samples

Affymetrix Human Human Exon 1.0 ST Array (huex10st), Affymetrix Human Exon 1.0 ST Array [probe set (exon) version (huex10st)

Submitter Supplied Information

Description

Acute myeloid leukemia (AML), and other myeloid malignancies, are frequently treated with hypomethylating agents like decitabine. Alterations in the epigenome, induced by decitabine, are likely to result in gene expression changes. The effects of decitabine have not been systemically studied using primary AML samples.

PubMed ID

23297133

Publication Title

Genomic impact of transient low-dose decitabine treatment on primary AML cells.

Total Samples

Submitter’s Institution

Washington University in St.Louis

Authors

Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, Lichti CF, Meyer MR, Townsend RR, Wilson RK, Mardis ER, Ley TJ

Source Repository

Gene Expression Omnibus (GEO)

Alternate Accession IDs

E-GEOD-40442

No rows found